BCTXZ Latest Press Releases

-- June 2, 2026 --

BriaCell Therapeutics Announces Closing of Offering Globe Newswire 4:05 PM

-- June 1, 2026 --

BriaCell Presents Positive Clinical Data at ASCO 2026 Globe Newswire 7:30 AM

-- May 31, 2026 --

BriaCell Therapeutics Announces Pricing of Offering Globe Newswire 7:59 PM

-- May 26, 2026 --

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer Globe Newswire 7:30 AM

-- May 22, 2026 --

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT at ASCO 2026 Globe Newswire 7:30 AM

-- May 15, 2026 --

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+ Globe Newswire 7:30 AM

-- May 14, 2026 --

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+ for Prostate Cancer Globe Newswire 7:30 AM

-- May 13, 2026 --

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study Globe Newswire 7:30 AM

-- May 12, 2026 --

BriaCell Phase 3 Bria-IMT Study Enrollment Surpasses 230 Patients Globe Newswire 7:30 AM

-- May 7, 2026 --

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study Globe Newswire 7:30 AM

-- May 6, 2026 --

BriaCell Receives FDA Clearance to Initiate Bria-BRES+ Clinical Study in Breast Cancer Globe Newswire 7:30 AM

-- April 27, 2026 --

BriaCell Announces Six Clinical Data Presentations at ASCO 2026 Globe Newswire 7:30 AM

-- April 21, 2026 --

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ in Preclinical Cancer Models Globe Newswire 7:30 AM

-- April 20, 2026 --

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting Globe Newswire 7:30 AM

-- March 31, 2026 --

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License Globe Newswire 4:05 PM

-- March 18, 2026 --

BriaCell to Present Positive Clinical Data for Bria-IMT and Preclinical Data for Next Generation Bria-OTS+ Personalized Immunotherapy at the 2026 AACR Conference Globe Newswire 7:30 AM

-- March 10, 2026 --

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting Globe Newswire 7:30 AM

-- March 5, 2026 --

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting Globe Newswire 4:04 PM

-- February 18, 2026 --

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License Globe Newswire 5:30 PM

-- February 17, 2026 --

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer Globe Newswire 7:30 AM

-- January 28, 2026 --

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation Globe Newswire 7:30 AM

-- January 27, 2026 --

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients Globe Newswire 7:30 AM

-- January 15, 2026 --

BriaCell Therapeutics Announces Closing of US$30 million Public Offering Globe Newswire 4:05 PM

-- January 13, 2026 --

BriaCell Therapeutics Announces Pricing of $30 million Public Offering Globe Newswire 9:00 PM

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS Patient Globe Newswire 7:30 AM